At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Montelukast on the Airway Remodeling in Asthma Patients: Physiological-radiological Correlation
In Brief
A Phase 4 clinical trial evaluating singular and placebo for Asthma. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The distal lung contributes to asthmatic airway remodeling which is observed from early onset of the disease. Cysteinyl leukotrienes (CysLT) play important role in the pathogenesis of airway remodeling and antileukotrienes work to exert a certain degree of anti-inflammatory effect. The cysteinyl leukotriene antagonist Montelukast has been in vivo shown to significantly inhibit ovalbumin induced airway smooth muscle hyperplasia and subepithelial fibrosis in sensitized mice. This study aims to evaluate if Montelukast could reverse airway remodeling in asthma patients by a non-invasive approach-HRCT.
Study Details
Timeline
Interventions
The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA